Cost-effectiveness analysis (CEA) was developed in response to demands for improving population health while controlling rising healthcare costs in the United States, Canada, and England in the late 20th century. Over time, CEA was refined and its theoretical foundations were expanded through its application to global health problems. While CEA is sometimes criticized for its use of cost-effectiveness ratios and thresholds, its durability is due to its basis in consequentialist moral philosophy and its ability to help coordinate resource allocation decisions across diverse groups.
Bobby Milstein, PhD, MPH, director of the ReThink Health and visiting scientist at MIT Sloan School of Management, gave the October 9 Grand Rounds on the Future of Public Health at Columbia's Mailman School of Public Health. Dr. Milstein's talk, "Beyond Reform and Rebound: Frontiers for Rethinking and Redirecting Health System Performance," was part of this year's Grand Rounds series focusing on the decline in the health status of the U.S. population compared to peer nations, as well as the opportunities for public health leadership that are needed to close this gap. While at the Mailman School, Dr. Milstein also met with a group of doctoral students and Prof. Ronald Bayer to discuss approaches to effectively improve health systems in the United States.
Visit the events page to find out more, http://www.mailman.columbia.edu/events/grand-rounds.
Final intro use of economic methods for injury prevention resource allocation John Wren
This 2010 paper was developed to address a range of information needs for the NZ Injury Prevention Secretariat, in particular:
1) a review of the health economics models and associated issues that must be understood when undertaking cost of injury studies
2) a review of the published New Zealand cost of injury studies to identify the methods utilised, and the size of the cost estimates calculated for various injury events
3) calculated a new total social and economic cost of injury estimate for all injuries and the six injury priority areas respectively, drawing upon the lessons learnt from the reviews undertaken
4) briefly reviewed the ways in which economic methods can be used to inform injury prevention investment decisions, and made recommendations for their use in New Zealand
5) drew conclusions and made recommendations about undertaking future cost of injury work to provide both better standardisation in approach and greater cost discrimination between injury areas.
Bobby Milstein, PhD, MPH, director of the ReThink Health and visiting scientist at MIT Sloan School of Management, gave the October 9 Grand Rounds on the Future of Public Health at Columbia's Mailman School of Public Health. Dr. Milstein's talk, "Beyond Reform and Rebound: Frontiers for Rethinking and Redirecting Health System Performance," was part of this year's Grand Rounds series focusing on the decline in the health status of the U.S. population compared to peer nations, as well as the opportunities for public health leadership that are needed to close this gap. While at the Mailman School, Dr. Milstein also met with a group of doctoral students and Prof. Ronald Bayer to discuss approaches to effectively improve health systems in the United States.
Visit the events page to find out more, http://www.mailman.columbia.edu/events/grand-rounds.
Final intro use of economic methods for injury prevention resource allocation John Wren
This 2010 paper was developed to address a range of information needs for the NZ Injury Prevention Secretariat, in particular:
1) a review of the health economics models and associated issues that must be understood when undertaking cost of injury studies
2) a review of the published New Zealand cost of injury studies to identify the methods utilised, and the size of the cost estimates calculated for various injury events
3) calculated a new total social and economic cost of injury estimate for all injuries and the six injury priority areas respectively, drawing upon the lessons learnt from the reviews undertaken
4) briefly reviewed the ways in which economic methods can be used to inform injury prevention investment decisions, and made recommendations for their use in New Zealand
5) drew conclusions and made recommendations about undertaking future cost of injury work to provide both better standardisation in approach and greater cost discrimination between injury areas.
Presentation given by Eric C. Schneider, MD, Senior Vice President for Policy and Research of The Commonwealth Fund at the University of Michigan Institute for Healthcare Policy and Innovation in Ann Arbor, MI on December 7, 2017.
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...Joanne Sienko Ott, CFA, MA
A value proposition exists at the intersection of two innovations - IM clinical practice and a crowdfunding research platform – at this nexus arises the potential solutions to address the U.S. healthcare Triple AIM: better care, better outcomes, lower costs. Crowdfunding is a “socially mediated phenomenon” based on intrinsic trust individuals place on shared connections and a willingness to fund projects or causes based on passion alone. What gets funded is what strikes a chord with funders. The passage of the 2012 JOBS Act has resulted in a flood of crowdfunding platforms that have raised over $5.1 billion. Crowdfunding is being utilized for medical research. Health philanthropists and impact investors are collaborating in new ways to make a bigger impact and build capacity, however they want to see buy-in before taking on risk. Crowdfunding mechanisms provide an automatic feedback loop for concepts and give indication of risk prior to investor venture. At the other side of this nexus a crippling healthcare system has produced lower outcomes/higher costs fast approaching 20% of GDP. Evidence suggests that IM practices is effective and could ease the pain in our healthcare system. Barriers exist for clinical practice of IM, based on lack of sufficient evidence and funded research. NCCIH’s portion of the total NIH budget remains at less than 1% and PCORI is not focused on comparative studies of conventional interventions with IM in seeking better outcomes. Creating a crowdfunding research platform is an intriguing proposition that could engage mindful investment in research methodology for IM clinical practices. At this nexus – a crowdfunding IM/CAM research platform - all those who are passionate about a healthcare system that promotes health creation and treats the whole person through holistic approaches that optimize healing, could be funders such as philanthropists, impact investors, patients, and practitioners alike.
Matching ecohealth and One Health attributes for emerging infectious diseases...ILRI
Poster by Theresa Burns, David Stephen, Manish Kakkar, Purvi Mehta-Bhatt, Hung Nguyen-Viet, Durgatt Joshi, Jennifer Dawson and Craig Stephen presented at the 5th biennial conference of the International Association for Ecology and Health (EcoHealth 2014), Montreal, Canada, 11−15 August 2014.
International Journal of Business and Management Invention (IJBMI)inventionjournals
International Journal of Business and Management Invention (IJBMI) is an international journal intended for professionals and researchers in all fields of Business and Management. IJBMI publishes research articles and reviews within the whole field Business and Management, new teaching methods, assessment, validation and the impact of new technologies and it will continue to provide information on the latest trends and developments in this ever-expanding subject. The publications of papers are selected through double peer reviewed to ensure originality, relevance, and readability. The articles published in our journal can be accessed online
The Link between Health Condition Costs and Standard of Living Through Out-of...Economic Research Forum
Eleftherios Giovanis - University of Verona
Oznur Ozdamar - Bologna University
ERF Workshop on The Economics of Healthcare in the ERF Region
Cairo, Egypt - May 23, 2016
www.erf.org.eg
Strengthening Health Systems: Lessons Learned from 2nd Decade of Thailand’s U...Borwornsom Leerapan
Special Symposium "Celebrating The Legacy of HRH Prince Mahidol of Songkla: A Century of Progress in Public Health and Medicine in Thailand", presented at Harvard University 2016.8.25
Presentation given by Eric C. Schneider, MD, Senior Vice President for Policy and Research of The Commonwealth Fund at the University of Michigan Institute for Healthcare Policy and Innovation in Ann Arbor, MI on December 7, 2017.
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...Joanne Sienko Ott, CFA, MA
A value proposition exists at the intersection of two innovations - IM clinical practice and a crowdfunding research platform – at this nexus arises the potential solutions to address the U.S. healthcare Triple AIM: better care, better outcomes, lower costs. Crowdfunding is a “socially mediated phenomenon” based on intrinsic trust individuals place on shared connections and a willingness to fund projects or causes based on passion alone. What gets funded is what strikes a chord with funders. The passage of the 2012 JOBS Act has resulted in a flood of crowdfunding platforms that have raised over $5.1 billion. Crowdfunding is being utilized for medical research. Health philanthropists and impact investors are collaborating in new ways to make a bigger impact and build capacity, however they want to see buy-in before taking on risk. Crowdfunding mechanisms provide an automatic feedback loop for concepts and give indication of risk prior to investor venture. At the other side of this nexus a crippling healthcare system has produced lower outcomes/higher costs fast approaching 20% of GDP. Evidence suggests that IM practices is effective and could ease the pain in our healthcare system. Barriers exist for clinical practice of IM, based on lack of sufficient evidence and funded research. NCCIH’s portion of the total NIH budget remains at less than 1% and PCORI is not focused on comparative studies of conventional interventions with IM in seeking better outcomes. Creating a crowdfunding research platform is an intriguing proposition that could engage mindful investment in research methodology for IM clinical practices. At this nexus – a crowdfunding IM/CAM research platform - all those who are passionate about a healthcare system that promotes health creation and treats the whole person through holistic approaches that optimize healing, could be funders such as philanthropists, impact investors, patients, and practitioners alike.
Matching ecohealth and One Health attributes for emerging infectious diseases...ILRI
Poster by Theresa Burns, David Stephen, Manish Kakkar, Purvi Mehta-Bhatt, Hung Nguyen-Viet, Durgatt Joshi, Jennifer Dawson and Craig Stephen presented at the 5th biennial conference of the International Association for Ecology and Health (EcoHealth 2014), Montreal, Canada, 11−15 August 2014.
International Journal of Business and Management Invention (IJBMI)inventionjournals
International Journal of Business and Management Invention (IJBMI) is an international journal intended for professionals and researchers in all fields of Business and Management. IJBMI publishes research articles and reviews within the whole field Business and Management, new teaching methods, assessment, validation and the impact of new technologies and it will continue to provide information on the latest trends and developments in this ever-expanding subject. The publications of papers are selected through double peer reviewed to ensure originality, relevance, and readability. The articles published in our journal can be accessed online
The Link between Health Condition Costs and Standard of Living Through Out-of...Economic Research Forum
Eleftherios Giovanis - University of Verona
Oznur Ozdamar - Bologna University
ERF Workshop on The Economics of Healthcare in the ERF Region
Cairo, Egypt - May 23, 2016
www.erf.org.eg
Strengthening Health Systems: Lessons Learned from 2nd Decade of Thailand’s U...Borwornsom Leerapan
Special Symposium "Celebrating The Legacy of HRH Prince Mahidol of Songkla: A Century of Progress in Public Health and Medicine in Thailand", presented at Harvard University 2016.8.25
Similar to The longest-lasting, most popular, and yet most thoroughly discredited idea in the history of modern public policy: cost-effectiveness analysis
Medical Governance, Health Policy, and Health Sector Reform in the PhilippinesAlbert Domingo
Suggested citation:
Domingo, Albert Francis E. "Medical Governance, Health Policy, and Health Sector Reform in the Philippines.” De La Salle Health Sciences Institute (DLSHSI). DLSHSI College of Medicine, Dasmarinas, Cavite. 27 Jun. 2014. Lecture.
Denis Cortese, M.D., president and CEO of Mayo Clinic, and Mayo Clinic Rochester chief administrative officer Jeff Korsmo presented highlights of the Mayo Clinic Health Policy Center's work on health care reform.
Health Economics In Clinical Trials - Pubricapubrica101
Pubrica specializes in Health Economics in Clinical Trials, offering comprehensive support to ensure the economic aspects of your trial are effectively managed. From cost-effectiveness analysis to budgeting and reimbursement strategies, we help you optimize the economic outcomes of your trial. With Pubrica's expertise, you can navigate the complex landscape of health economics in clinical trials with confidence.
For more information, please refer to our service- https://pubrica.com/blog/research/health-economics-in-clinical-trials/ & Order now - https://pubrica.com/order-now/
Contact Our UK Medical Author’s;
Our email id – sales@pubrica.com
Contact No. +91 9884350006
Rethinking Value Based Healthcare
Around the world healthcare providers are busy exploring how value-based healthcare can both improve the efficiency and effectiveness of healthcare delivery and seed new opportunities for innovation. Continuing our collaboration with Denmark, we are very pleased to release a new perspective on how VBHC can have greater impact in practice. Based on insights from a recent event hosted by DTU Executive Business Education and undertaken in partnership with Rethink Value, this point of view looks at the key issues for patients, physicals, providers and payers.
It explores some of the associated implications for healthcare systems worldwide, highlights several leading early examples of VBHC in practice and looks at how it can have impact at scale. Recommendations focus on the structure of care, key metrics, moving beyond pilots, changes in reimbursement models and the need for greater insight sharing and deeper collaboration.
For related Future Agenda research see www.futureofpatientdata.org
HeadnoteGovernments with universal healthcare systems are increa.docxisaachwrensch
Headnote
Governments with universal healthcare systems are increasingly bemoaning the costs of their systems and the need to contain these costs if affordable healthcare services are to be sustained into the future. In a bid to reduce the costs of healthcare, politicians and bureaucrats have championed the need for reform. Although avoiding the language of rationing, the kinds of 'reforms' being championed (eg. greater government regulation of universal health coverage, reducing reimbursement for medical costs, cutting funding to public hospitals) seem however, to be more concerned with restricting universal healthcare coverage, rather than reforming it.
The rhetoric of healthcare reforms has also had a political ideological objective shifting the provision of and accountability for public healthcare services to private sector providers. This objective has been pursued despite experts warning that such a shift will ultimately lead (and in some cases has already led) to inequities and unjust disparities in access to healthcare and related health outcomes, especially in vulnerable populations who cannot afford private health insurance.
Australia has not been immune from ideologically driven machinations about the sustainability of its universal healthcare scheme, ie. Medicare. Despite health expenditure in Australia reportedly reaching a record low for the period 2012-2013, there has been a political campaign of spreading false and misleading information about Medicare's sustainability (Keast 2015).This misinformation has included 'blaming' vulnerable populations (eg. an ageing demographic, the 'undeserving poor') for their allegedly disproportionate over-utilisation of public healthcare services and the need to curb this costly 'wanton' demand. What has been overlooked in this situation, however, is that a key driver of the spiraling costs of healthcare is not the over-utilisation of services by people in need, but rather 'the use of wasteful tests and treatments' prescribed by doctors (Tilburt & Cassel, 2013) together with the rising costs of drugs (driven by the business behaviours of the pharmaceutical industry) and medical technology, particularly in hospitals. Also overlooked is the problem of language and the tendency to treat the terms 'healthcare', 'hospital care', and 'medical care' as being synonymous, when they are not. Failure to distinguish what each of these terms refers to unnecessarily muddles debate about what healthcare reforms are needed as well as where and how these should occur.
Question of nursing ethics
The ethics of healthcare rationing has been the subject of debate for decades. This debate has primarily rested on the issue of whether it is ever acceptable to ration healthcare and, if so, on what grounds. It has also prompted unresolved controversies about the interests of individuals versus the collective interests of society in accessing limited healthcare resources and how best to balance these competing inter.
Florida State UniversityCollege of Nursing and Health Sciences.docxAKHIL969626
Florida State University
College of Nursing and Health Sciences
(CNHS)
HSA 526 - “Health Care Economics”
Individual Assignments/Projects
Assigned Readings
(20% of the final grade)
Instructions and Grading Scales
Instructor: Michael Durr, CPA, MHSA, CHFP
Individual projects and presentations are designed to develop competencies in students while exploring and exposing the challenges and importance of what health care professionals need to do to be successful.
Individual projects should reflect your own work, having done research, applied material from the course, and demonstrate critical thinking. Based on the subject matter of the assigned reading, your paper will reflect one or more of the following:
1. Identify and describe the components of the healthcare system in US;
2. Distinguish between the demand for health, healthcare, and health insurance;
3. Use basic cost - benefit analysis;
4. Identify and describe the role of the key players in the supply of healthcare;
5. Describe the role of government in our current health care system;
6. Identify the major economics related research questions and challenges being asked in the areas of health insurance provision, the pharmaceutical industry, the physician services industry and the long term care industry;
7. Compare and contrast the healthcare delivery system of various countries;
8. Use economic analysis to understand and criticize the changes in the healthcare system.
All documents should be prepared using the APA format. Submission subsequent to the due date will result in a reduction of 10 full points for each day or partial day late.
Instructions:
1. Based on the Assigned Reading for the week, you will prepare a two to three page critique of the paper.
2. All papers will include the standard Barry cover letter and follow APA format.
3. Your critique needs to include research based on at least two other acceptable sources (i.e. Wikipedia is not acceptable).
4. Be concise in your writing – do NOT use “fluff” (such as excessive retelling of original material from the reading or a large restatement of the situation).
5. Your grade will depend largely on the application of economic concepts and your critical thinking skills.
6. Your paper needs to have a conclusion one way or another. Do not vacillate or hedge. Your opinion counts and so make it heard!
M. Durr 1
NBER WORKING PAPER SERIES
IS HOSPITAL COMPETITION
SOCIALLY WASTEFUL?
Daniel P. Kessler
Mark B. McClellan
Working Paper 7266
http://www.nber.org/papers/w7266
NATIONAL BUREAU OF ECONOMIC RESEARCH
1050 Massachusetts Avenue
Cambridge, MA 02138
July 1999
We would like to thank David Becker, Kristin Madison, and Abigail Tay for exceptional research assistance.
Participants in the University of Chicago, Econometric Society, National Bureau of Economic Research,
Northwestern University, U.S. Department of Justice/Federal Trade Commission, and Harvard/MIT industrial
organization seminars provided numerous helpful ...
Design Research and Healthcare Reform - Mayo Clinic ProceedingsChristine Chastain
Meaningful health reform in the United States must improve the health of the population while lowering costs. In an effort to provide a framework for doing so, the Institute of Health Care Improvement created the triple aim, which encompasses the goals of (1) improv- ing individual health and experience with the health care system, (2) improving population health, and (3) decreasing the rate of per capita health care costs. Current reform efforts have focused on the development of Patient-Centered Medical Homes (an innovative team-based model of care that facilitates a partnership between the patient's personal physician coordinating care throughout a pa- tient's lifetime to maximize health outcomes), but these relatively narrow efforts are focused on office practice and payment methods and are not generally oriented toward community needs. We sought to apply design research in assessing a community opportunity to apply the triple aim as a strategy to transform health care delivery.
Future of Healthcare – Leadership Challenges
Further to several additional expert workshops this year, we are delighted to share an updated global perspective on the future of healthcare. Produced in partnership with Duke Corporate Education (http://www.dukece.com), this adds new insights on the pivotal shifts taking place across the sector plus viewpoints on some of the core implications for leadership. Topics include the growing power of data; the rising impact of urbanisation on health; increasing patient centricity; the need for more flexible organisations and the move of innovation activity eastwards.
Available as both this report and as an accompanying presentation (https://www.slideshare.net/futureagenda2/future-of-healthcare-15-october-2019-182433390) this is now being used to inform and provoke further debate around the world. As ever we would like to thank all those who have given their time and insight to contribute to this project.
Week 9 AssignmentContinue on with building your final applicatio.docxphilipnelson29183
Week 9 Assignment
Continue on with building your final application due in week 10. You will submit one cogent paper that combines the previous two applications (Parts One and Two) from weeks 4 and 7, plus the new material mentioned in the week 8 application
Application: Developing a Health Advocacy Campaign
To be an effective advocate and to develop a successful health advocacy campaign, you must have a clear idea of the goals of your campaign program and be able to communicate those goals to others. In addition, it is the nature of nurses to want to help, but it is important to make sure that the vision you develop is manageable in size and scope. By researching what others have done, you will better appreciate what can realistically be accomplished. It is also wise to determine if others have similar goals and to work with these people to form strategic partnerships. If you begin your planning with a strong idea of your resources, assets, and capabilities, you will be much more likely to succeed and truly make a difference with those you hope to help.
You will develop a 10- to 12-page paper that outlines a health advocacy campaign designed to promote policies to improve the health of a population of your choice. This week, you will establish the framework for your campaign by identifying a population health concern of interest to you. You will then provide an overview of how you would approach advocating for this issue.
-In Week 9, you will consider legal and regulatory factors that have an impact on the issue and finally, in Week 10, you will identify ethical concerns that you could face as an advocate. Specific details for each aspect of this paper are provided each week.
This paper will serve as the Portfolio Application for the course.
Before you begin, review the complete Assignment.
This week, begin developing your health advocacy campaign by focusing on the following:
Week 10 Application
To prepare for this final portion of your paper:
· Review provisions 7, 8, and 9 of the ANA Code of Ethics in relation to advocacy for population health.
· Reflect on the ethical considerations you may need to take into account in your advocacy campaign.
· Research the ethical considerations and lobbying laws relevant to the location where your advocacy campaign will occur.
· Consider potential ethical dilemmas you might face in your campaign.
To complete: Revise and combine parts one and two of you previous papers and add the following:
· Explain any ethical dilemmas that could arise during your advocacy campaign, and how you would resolve them.
· Describe the ethics and lobbying laws that are applicable to your advocacy campaign.
· Evaluate the special ethical challenges that are unique to the population you are addressing.
· Provide a cohesive summary for your paper.
Reminder: You will submit one cogent paper that combines the previous applications (Parts One and Two) plus the new material.
Your paper should be about 10 pages of content, n.
Engines of Success for U.S. Health Reform?
Eric B. Larson, MD, MPHVice President for Research, Group Health Executive Director, Group Health Research Institute
Introduction to health economics for the medical practitionerDr Matt Boente MD
Against a background of increasing demands on limited resources, health economics is exerting an influence on decision making at all levels of health care. Health economics seeks to facilitate decision making by offering an explicit decision making framework based on the principle of efficiency. It is not the only consideration but it is an important one and practitioners will need to have an understanding of its basic principles and how it can impact on clinical decision making. This article reviews some of the basic principles of health economics and in particular economic evaluation.
This two page summary outlines the American Health Care System quality and cost issues and offers the only practical business solution.
Similar to The longest-lasting, most popular, and yet most thoroughly discredited idea in the history of modern public policy: cost-effectiveness analysis (20)
Do height and BMI affect human capital formation? Natural experimental evidence from DNA. CHE seminar presentation by Neil Davies, University of Bristol 12 June 2020
Healthy Minds: A Randomised Controlled Trial to Evaluate PHSE Curriculum Deve...cheweb1
CHE Seminar presentation 16 January 2020, Alistair McGuire, Department of Health Policy, LSE. Evaluating the Healthy Minds program: The impact on adolescent’s health related quality of life of a change in a school curriculum
Baker what to do when people disagree che york seminar jan 2019 v2cheweb1
Public values, plurality and health care resource allocation: What should we do when people disagree? (..and should economists care about reasons as well as choices?) CHE Seminar 21 January 2019
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Evaluation of antidepressant activity of clitoris ternatea in animals
The longest-lasting, most popular, and yet most thoroughly discredited idea in the history of modern public policy: cost-effectiveness analysis
1. The longest-lasting,
most popular
(and yet most thoroughly discredited)
idea
in the history of
modern public policy
Jeremy A. Lauer, PhD
Economist
Economic Analysis and Evaluation
Health Systems Governance and Financing
3. 1. Identify CEA’s connections to social choice and
– enumerate the reasons explaining its durability.
2. Review the foundations of CEA and
– clarify points of confusion.
3. Articulate an account of generalized CEA that differs
from, and
– is more liberal than, the standard version.
4. Reconcile disputes between generalized and
incremental CEA, and
– explain the source of controversies around threshold-
based rules in decision-making.
5. Link the theory of generalized CEA to real-world
decision making in a novel way.
What I said I would do
4. “The rapid and continuing growth of expenditures is a central
issue in many policy decisions concerning the medical care
system .... Policymakers, health professionals, and consumers
are seeking ways to control this growth while simultaneously
improving the quality of health care. Increasingly, the use of
cost-effectiveness analysis ... is being advocated...”
United States Congress Office of Technology Assessment. The Implications of Cost-
Effectiveness Analysis of Medical Technology, Washington, DC, 1980.
How to begin an article, 1980
5. “It has become increasingly popular to carry out cost-
effectiveness analyses in economic evaluations of healthcare
programmes.”
Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis.
Pharmacoeconomics. 1996 Feb;9(2):113-20.
How to begin an article, 1993
6. “An increasing number of health-care systems, both public
and private, such as managed-care organizations, are adopting
results from cost-effectiveness analysis as one of the
measures to inform decisions on allocation of health-care
resources.”
Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis
in health-care resource allocation decision-making: how are cost-effectiveness
thresholds expected to emerge? Value Health, 7(5):518-28, 2004.
How to begin an article, 2004
7. “… cost-effectiveness analysis (CEA) studies ... are routinely used
around the globe to inform priority setting in health care and public
health....”
Cookson R, Mirelman AJ, Griffin S, Asaria M, Dawkins B, Norheim OF, Verguet S, J Culyer A.
Using Cost-Effectiveness Analysis to Address Health Equity Concerns. Value Health,
20(2):206-212, 2017.
How to begin an article, 2017
8. “…decisions about whether to adopt technologies and
services in publicly funded benefit packages, involve balancing
health gains against the costs of the required resources: more
and more frequently this is done in an explicit way, on the
basis of analyses that build upwards from the biomedical
evidence to create information to support decision makers in
coming to judgements about value for money.”
Lauer et al., in preparation, 2018
How to begin, again, 2018
11. Or possibly it’s just a goldfish story*
*“It looks like new scenery,
every time!”
12. “I’m still where I was 40 years ago!”
In few fields of science can one claim:
13. Why is CEA so robust?
1. CEA expresses the idea that health is an
intrinsic benefit (i.e. it counts in its own
terms).
– Important distinction w.r.t. its main competitor,
benefit-cost analysis.
14. 2. CEA is rational:
– It respects individual autonomy.
– It is objective (i.e. it uses scientific methods which
are subject to continual open-source review).
– It is impartial to persons.
Why is CEA so robust?
15. Two mainstreams in moral philosophy
• Kant: Deontological concerns about rules of action:
the stream MCDA is in.
• Sidgwick: Utilitarian consequentialism:
the stream CEA is in.
16. 3. It belongs to a mainstream of moral
philosophy:
– the idea that actions should be judged by their
outcomes, or consequences, and
– that causal modelling can capture and organize
knowledge about the relevant states of the
world.
Why is CEA so robust?
17. 4. CEA solves a “coordination problem”
– how do disparate groups of people organize
themselves around a particular action or set of
actions?
– In economics, also called the problem of vertical
integration.
Why is CEA so robust?
18. 1. United States Congress Office of Technology Assessment. The Implications of
Cost-Effectiveness Analysis of Medical Technology, Washington, DC, 1980.
2. Drummond M, O’Brien B, Stoddart G, et al. Methods for the Economic
Evaluation of Health Care Programmes, Oxford University Press, 1987.
3. Canadian Coordinating Office for Health Technology Assessment. Guidelines
for economic evaluation of pharmaceuticals, Ottawa, Canada: Canadian
Coordinating Office for Health Technology Assessment, 1994.
4. Gold M, Siegel J, Russell L, et al. Cost-effectiveness in Health and Medicine.
New York & Oxford: Oxford University Press, 1996.
5. World Health Organization. Guide to Cost-Effectiveness Analysis, Geneva:
World Health Organization, 2003.
6. Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied Methods of
Cost-effectiveness Analysis in Health Care, Oxford, 2011.
7. Wilkinson T, Sculpher MJ, Claxton K, et al. The International Decision Support
Initiative Reference Case for Economic Evaluation: An Aid to Thought. Value
Health, 2016; 19: 921-928.
Evolution is a fact
19. Cost-effectiveness analysis was developed and
refined in response to the demands of specific
settings:
– during the latter years
of the 20th century
– in the United States,
Canada and England
– [Refs 1, 2, 3, 4].
Beginnings matter
20. There was a perception, in those days, on the part
of decision makers, in those settings, that they had
a mandate to improve the health of populations:
through the regulation, financing or direct provision of
health services.
A la recherche du temps perdu…
21. The 1980 report of the “Office
of Technology Assessment of
the United States Congress”
cites over 650 references:
– applying economic analysis to healthcare,
– virtually all published in the 1970s, and
– a substantial minority of which were published by
government agencies.
The hard progress of experience
22. • In the early years of this century, staff at the
WHO became interested in the application of
cost-effectiveness analysis to health problems
in developing countries [Ref 5].
• Hundreds (if not thousands) of scientific
papers applying CEA to global health problems
have since been published.
New horizons
23. • The technical basis of CEA evolved to support the needs of
actors operating in a variety of jurisdictions.
• For example, generalized cost effectiveness analysis
(GCEA) was ostensibly created with the needs of lower
income countries in mind:
– not to solve the problem of the growing costs of medical care,
– but to prioritize essential services for under-served populations.
• Yet GCEA inevitably picked up themes from contemporary
debates, in particular, those about health maximization
and decision rules.
Changes in practice bring
changes in theory
24. • Birch S, Gafni A. Cost effectiveness/utility analyses.
Do current decision rules lead us to where we want
to be? J Health Econ. 1992 Oct; 11(3):279-96.
• Johannesson M, Weinstein MC. On the decision rules
of cost-effectiveness analysis. J Health Econ. 1993
Dec;12(4):459-67.
Do decision rules maximize health?
25. 1. So-called generalized cost-effectiveness
analysis:
– based on health maximization
– (not thresholds).
2. So-called incremental (or marginal) cost-
effectiveness analysis:
– based on decision rules
– involving thresholds.
Two schools of thought
29. Starting points and portfolios matter*
*Acknowledgements to Richard Cookson for this clarification.
30. • Interest in obtaining value for money for
health in developing countries continues to
grow:
– the founding of the International Decision
Support Initiative [Ref 7], and
– the increasing use of CEA by a variety of domestic
stakeholders and decision makers in developing
and emerging economies.
Global health, no longer public health
31. • In the guidelines, over the years, CEA is given
various justifications, often based
on common sense principles.
• However, CEA contains a cryptic
sub-text, known only to a few…
• CEA’s gnostic doctrine comes
from duality theory for linear programming.
The hidden story of CEA
33. • WZ introduced the powerful idea of
mathematical programming to CEA.
• WZ also made CEA’s first* giant strategic
blunder:
– anchoring the notion of critical ratios in the
mythology of CEA.
• This resulted in lasting harms:
– notably, controversies over ratio-centric cost-
effectiveness thresholds.
“No hay bien que por mal no venga”
(every silver lining brings its cloud)
*The second giant mistake was arguably the (self-defeating) “CHOICE GDP thresholds”.
35. • CEA was not pre-destined to have a ratio-centric
theory:
– nothing pre-determined about this,
– witness the many book-length guidelines.
• CEA could equally have been developed around
the concept of net benefit analysis, net cost
analysis or even just opportunity cost analysis.
• The latter is arguably the fundamental concept of
CEA, not critical ratios.
Different possible pasts for CEA
36. 1. Lagrangian constrained optimization.
2. Duality theory in linear programming.
• For our purposes, they’re the same:
– Both involve optimal E/C ratios.
• Because convex optimization, KKT theory, and
mathematical programming are the primary
superstructure of modern mathematical economics,
we’ll use the latter form of the problem (duality).
There are two sources of critical ratios
37. The formulation of WZ is that of the primal of
the linear-programming “knapsack problem”.
38. The critical ratio comes from the dual
of the knapsack problem
(N.B. There’s no critical ratio in the primal knapsack
problem.)
40. The combination of:
– Linear programming (e.g. the simplex method of 1947,
without critical ratios), and
– Duality for linear programming, with critical ratios).
• These ideas go so well together that they usually
come pre-mixed:
Once you’ve seen it, you can’t unsee it
41. Duality is hard
(From the Preface to Nering ED, Tucker AW. Linear Programming and
Related Problems. Boston, MA: Academic Press, 1993.)
42. • Informal communications from George Dantzig:
– Duality for linear programming conjectured by John
von Neumann.
– Proved by Albert Tucker, post-WWII at Princeton:
• Some standard sources on duality are:
– Dantzig et al., 1956
– Luenberger, 1973;
– Nering and Tucker, 1993
– Bertsekas, 1995.
Duality is new
43. • Weinstein and Zeckhauser, 1973.
• On the glass-half-full view, without WZ:
– health economics would probably still be called
medical economics, and
– we’d possibly still be doing cost of illness studies, à
la Dorothy Rice.
• COI/CBA being the larger part of what
predated the emergence of CEA in health
economics.
Duality is contemporary to the
codification of CEA
44. 1. Focus on optimal portfolios (WHO-CHOICE).
2. Redefine thresholds (York CHE).
Two possible resolutions to CEA’s
critical ratio problem
45. York approach
What's in, what's out : designing benefits for universal health coverage
edited by Amanda Glassman, Ursula Giedion, and Peter C. Smith.
46. • Are a summary measure of opportunity cost.
• Are a measure of the marginal productivity of
the health system.
• Are a shortcut that avoids the need to
quantify the costs and benefits of all feasible
interventions.
• Are a measure of the health people forgo
when other options are funded than the ones
that would benefit them.
York thresholds are not ratios - they:
49. Current portfolio Optimal portfolio
Health system factors
Politics
Affordability
“Dismal realist” view of Efficient Allocation
We may never
get there…
50. • A given optimal portfolio requires a particular type of
health system, with a particular set of fixed assets.
• Information about the contents of the portfolio allows
actors in the health system to coordinate their choices.
• Human resources and facilities, and logistics and supply
networks, are fixed assets that are not replaceable,
transferable or created in the short term.
• Information about the optimal portfolio should
influence most decisions about asset-specific
investments.
• This is one of the meanings of priority setting –
determining which asset-specific investments to make.
CHOICE view of Efficient Allocation
51. Two kinds of decision-making
(N.B. they are not strongly method dependent)
• Localized, or incremental, decision-making:
– Starts from current situation and adds things one at a time,
– Often uses a threshold (of some kind).
• Strategic, context-setting, decision-making:
– Looks at many things at once, including the current
portfolio,
– Usually employs explicit maximization; sometimes uses a
threshold.
• When CEA is used to support localized decisions, we
term it incremental cost-effectiveness analysis (ICEA).
• When CEA is used to support strategic decisions, we
call it generalized cost-effectiveness analysis (GCEA).